Prudential Financial
TCRX icon

Prudential Financial’s TScan Therapeutics TCRX Stock Holding History

Prudential Financial’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.1K Buy
29,800
+5,400
+22% +$5.77K ﹤0.01% 2364
2025
Q4 		$24.4K Buy
24,400
+12,900
+112% +$18.7K ﹤0.01% 2188
2025
Q3 		$20.9K Buy
+11,500
New +$20.4K ﹤0.01% 2399
2025
Q2 		– Sell
-10,995
Closed -$15.2K – 2513
2025
Q1 		$15.2K Buy
10,995
+580
+6% +$1.25K ﹤0.01% 2268
2024
Q4 		$31.7K Buy
+10,415
New +$47.2K ﹤0.01% 2253
2023
Q1 		– Sell
-12,800
Closed -$20.9K – 2673
2022
Q4 		$20.9K Buy
12,800
+1,800
+16% +$4.41K ﹤0.01% 2565
2022
Q3 		$34K Buy
+11,000
New +$36K ﹤0.01% 2592

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Prudential Financial's TCRX Position: Q1 2026 in Review

Prudential Financial increased its TScan Therapeutics (TCRX) stake by 22% in Q1 2026, buying an estimated $5.77K and bringing the position to 29,800 shares worth $30.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2364.

Prudential Financial first reported a position in TCRX in Q3 2022 and has held it in 7 quarters since. The position peaked at $34K in Q3 2022. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Prudential Financial held 29,800 shares of TScan Therapeutics worth $30.1K as of Q1 2026.
  • Prudential Financial bought 5,400 TScan Therapeutics shares in Q1 2026, an estimated $5.77K.
  • TScan Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2364 holding.
  • Prudential Financial first reported a position in TScan Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • Prudential Financial's TScan Therapeutics position peaked at $34K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.